Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Receives $50.33 Consensus Target Price from Analysts

Shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN) have been assigned a consensus rating of “Hold” from the eleven analysts that are presently covering the firm, MarketBeat reports. Eight research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1 year price target among brokers that have covered the stock in the last year is $50.33.

A number of research firms recently commented on ALPN. Wedbush lowered shares of Alpine Immune Sciences from an “outperform” rating to a “neutral” rating in a research note on Thursday, April 11th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $65.00 target price (up previously from $47.00) on shares of Alpine Immune Sciences in a research report on Thursday, April 11th. Guggenheim began coverage on Alpine Immune Sciences in a research report on Tuesday, April 9th. They set a “buy” rating and a $55.00 price target on the stock. Leerink Partnrs downgraded Alpine Immune Sciences from an “outperform” rating to a “market perform” rating in a research note on Thursday, April 11th. Finally, HC Wainwright cut Alpine Immune Sciences from a “buy” rating to a “neutral” rating in a research note on Thursday, April 11th.

Alpine Immune Sciences Stock Down 0.0 %

NASDAQ:ALPN opened at $64.55 on Friday. The stock has a fifty day simple moving average of $41.49 and a 200 day simple moving average of $25.72. The firm has a market capitalization of $4.23 billion, a price-to-earnings ratio of -100.86 and a beta of 1.14. Alpine Immune Sciences has a 1-year low of $6.71 and a 1-year high of $64.70.

Alpine Immune Sciences (NASDAQ:ALPN) last announced its earnings results on Monday, March 18th. The biotechnology company reported $0.15 EPS for the quarter, topping the consensus estimate of ($0.32) by $0.47. The company had revenue of $30.85 million during the quarter, compared to analysts’ expectations of $6.90 million. Alpine Immune Sciences had a negative net margin of 54.66% and a negative return on equity of 15.54%. Equities analysts predict that Alpine Immune Sciences will post -1.74 earnings per share for the current year.

Institutional Investors Weigh In On Alpine Immune Sciences

Hedge funds and other institutional investors have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. increased its stake in shares of Alpine Immune Sciences by 429.8% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,723 shares of the biotechnology company’s stock worth $128,000 after purchasing an additional 5,454 shares during the last quarter. Walleye Capital LLC increased its position in Alpine Immune Sciences by 13.1% during the third quarter. Walleye Capital LLC now owns 186,273 shares of the biotechnology company’s stock worth $2,133,000 after buying an additional 21,600 shares during the last quarter. Vanguard Group Inc. increased its position in Alpine Immune Sciences by 5.1% during the third quarter. Vanguard Group Inc. now owns 1,474,879 shares of the biotechnology company’s stock worth $16,887,000 after buying an additional 70,912 shares during the last quarter. Nan Fung Group Holdings Ltd bought a new position in Alpine Immune Sciences during the third quarter valued at about $2,087,000. Finally, Schonfeld Strategic Advisors LLC lifted its holdings in Alpine Immune Sciences by 604.9% in the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 90,937 shares of the biotechnology company’s stock worth $1,041,000 after purchasing an additional 78,037 shares during the last quarter. 75.17% of the stock is owned by hedge funds and other institutional investors.

Alpine Immune Sciences Company Profile

Alpine Immune Sciences, Inc operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus.